A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Trial Status: Closed to Accrual
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Inclusion Criteria
- Advanced Renal Cell Carcinoma
- Must have at least 1 lesion with measurable disease
- Life expectancy of at least 3 months
- Karnofsky Performance Status (KPS) must be =>70%
Exclusion Criteria
- Patients/subjects with suspected or known central nervous system metastases unless adequately treated
- Patients/subjects with autoimmune disease
- Patients/subjects who need daily oxygen therapy
Connecticut
New Haven
Yale University
Status: TEMPORARILY_CLOSED_TO_ACCRUAL
Maryland
Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: CLOSED_TO_ACCRUAL
Massachusetts
Boston
Brigham and Women's Hospital
Status: CLOSED_TO_ACCRUAL
Dana-Farber Cancer Institute
Status: CLOSED_TO_ACCRUAL
Massachusetts General Hospital Cancer Center
Status: CLOSED_TO_ACCRUAL
Michigan
Detroit
Wayne State University / Karmanos Cancer Institute
Status: CLOSED_TO_ACCRUAL
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: CLOSED_TO_ACCRUAL
New York
Buffalo
Roswell Park Cancer Institute
Status: CLOSED_TO_ACCRUAL
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ADMINISTRATIVELY_COMPLETE
Ohio
Columbus
Ohio State University Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Oregon
Portland
OHSU Knight Cancer Institute
Status: CLOSED_TO_ACCRUAL
South Carolina
Charleston
Medical University of South Carolina
Status: COMPLETED
Texas
Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: CLOSED_TO_ACCRUAL
Contact: Marcella West Aguilar
Phone: 214-648-1479
Virginia
Charlottesville
University of Virginia Cancer Center
Status: CLOSED_TO_ACCRUAL
Washington
Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: CLOSED_TO_ACCRUAL
Trial Phase Phase II
Trial Type Treatment
Lead Organization
Bristol-Myers Squibb
- Primary ID CA018-005
- Secondary IDs NCI-2017-00404, 2016-003082-26
- Clinicaltrials.gov ID NCT02996110